Researchers at Memorial Sloan Kettering Cancer Center have developed a training program to help health providers reduce lung cancer stigma. In this interview, they discuss an ongoing NCI-funded nationwide clinical trial to test the training.
Tag: Lung Cancer
Tumor DNA in the blood can predict lung cancer outcome
Scientists have found that a test to detect circulating tumor DNA can predict lung cancer outcome.
Cancer Today’s Winter 2024-25 Issue: Reducing the Burden of Radiation, Why Geriatric Assessment is Critical to Care, and More
After Tiffany Fagnani was diagnosed with stage 4 non-small cell lung cancer that had spread to her brain in July 2017, she began targeted therapy and underwent surgery to remove the brain tumor. To kill any cancerous cells that remained, Fagnani also received radiation. In past years, she would have received whole brain radiation treatment,… Continue reading Cancer Today’s Winter 2024-25 Issue: Reducing the Burden of Radiation, Why Geriatric Assessment is Critical to Care, and More
Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics
Introduction Immune checkpoint inhibitors (ICI) have improved outcomes in non-small cell lung cancer (NSCLC). Nevertheless, the clinical benefit of ICI as monotherapy or in combination with chemotherapy remains widely varied and existing biomarkers have limited predictive value. We present an analysis of ENLIGHT-DP, a novel transcriptome-based biomarker directly from histopathology slides, in patients with lung… Continue reading Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics
Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein–overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib
Osimertinib is the standard first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutated NSCLC. However, treatment resistance is inevitable and increased c-Met protein expression correlates with resistance. Telisotuzumab vedotin (Teliso-V) is an antibody-drug conjugate that targets c-Met protein overexpression. Herein, we report the results of a phase 1/1b trial evaluating Teliso-V plus osimertinib in patients… Continue reading Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein–overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib
Experts Forecast Cancer Research and Treatment Advances in 2025
Every new year brings excitement and anticipation for what might happen over the next 12 months. So, what’s in store for 2025 that could change the way we diagnose and treat cancer? What first-in-class therapeutics could offer new life-saving options to patients? What scientific discovery will have everyone talking? In 2024, we saw the approval… Continue reading Experts Forecast Cancer Research and Treatment Advances in 2025
A new turning point in lung cancer treatment, inspired by mussels
Scientists have developed inhalable lung cancer therapeutics utilizing mucoadhesive proteinic nanoparticles.
Lung cancer test predicts survival in early stages better than current methods
Researchers have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors. This could help doctors make more informed treatment decisions for people with stage 1 lung cancer, potentially reducing the risk of the cancer returning or spreading.
Uncertain Prognostic Impact of Visceral Pleural Invasion—Reply
In Reply We thank Köylü and Güven for their critique of our recently published article that examined the association of visceral pleural invasion (VPI) with recurrence and survival in patients with peripheral clinically node-negative non–small cell lung cancer 2 cm or smaller in size who were randomized to lobar or sublobar resection in the CALGB… Continue reading Uncertain Prognostic Impact of Visceral Pleural Invasion—Reply
Uncertain Prognostic Impact of Visceral Pleural Invasion
To the Editor We read the article by Altorki et al, reporting that the presence of visceral pleural invasion (VPI) was associated with higher recurrence rates and poorer survival in patients with small (≤2 cm) peripheral non–small cell lung cancer (NSCLC) independent of the extent of resection (lobar vs sublobar). The authors suggested that patients… Continue reading Uncertain Prognostic Impact of Visceral Pleural Invasion